iroxanadine

structure in first source

Also Known As:

5,6-dihydro-5-(1-piperidinyl)methyl-3-(3-pyridil)-4H-1,2,4-oxa-diazine; 5,6-dihydro-5-(1-piperidinyl)methyl-3-(3-pyridyl)-4H-1,2,4-oxadiazine; BRX 235; BRX-235; BRX235; cytrx

Networked: 6 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - iroxanadine: 6
  - Oxazines: 9
    - iroxanadine: 6

Experts

1.	Cernak, Ibolja: 1 article (01/2011)
2.	Erokwu, Bernadette O: 1 article (01/2011)
3.	Lamanna, Joseph C: 1 article (01/2011)
4.	Sun, Xiaoyan: 1 article (01/2011)
5.	Xu, Kui: 1 article (01/2011)
6.	Cortes, Jorge: 1 article (12/2010)
7.	Kantarjian, Hagop: 1 article (12/2010)
8.	Quintas-Cardama, Alfonso: 1 article (12/2010)
9.	Santos, Fabio P S: 1 article (12/2010)
10.	Phukan, Julie: 1 article (07/2010)

Related Diseases

1.	Hypoxia (Hypoxemia) 12/01/2004 - "Addition of BRX-235 (0.1-1 microM) to culture medium prior to hypoxia or at start of reoxygenation significantly reduced the caspase-dependent apoptosis. " 03/01/2008 - "The aim of this study is to assess whether treatment of cells after hypoxia by Iroxanadine heat-shock protein (HSP-coinducer) predicts recovery through cell proliferation. " 01/01/2011 - "We investigated the effect of a heat-shock protein co-inducer, arimoclomol (CytRx, LA, CA), on hypoxia-adaptive responses using a rat model of simulated altitude exposure (hypobaric hypoxia).Cognitive function was measured using a T-maze and an object recognition test.Motor"
2.	Acute Lung Injury 04/01/1999 - "CytRx is developing Flocor, an amphipathic copolymer, as a potential treatment for acute sickle cell crisis and acute respiratory distress syndrome (ARDS)/acute lung injury 1. It is currently undergoing phase III clinical trials for the treatment of sickle cell crisis. "
3.	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 04/01/1999 - "CytRx is developing Flocor, an amphipathic copolymer, as a potential treatment for acute sickle cell crisis and acute respiratory distress syndrome (ARDS)/acute lung injury 1. It is currently undergoing phase III clinical trials for the treatment of sickle cell crisis. "
4.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/01/2010 - "Bafetinib (NS-187, INNO-406) is a second-generation tyrosine kinase inhibitor in development by CytRx under license from Nippon Shinyaku for treating Bcr-Abl+ leukemia's, including chronic myelogenous leukemia (CML) and Philadelphia+ acute lymphoblastic leukemia. "
5.	Atherosclerosis 12/01/2004 - "BRX-235 (Iroxanadine), a novel drug developed by Biorex (Hungary), was previously characterized as a vasculoprotector against atherosclerosis, an activator of p38 kinase, and an enhancer of stress-responsive heat shock protein (Hsp) expression. "

Related Drugs and Biologics

1.	Heat-Shock Proteins (Heat-Shock Protein)
2.	arimoclomol
3.	iroxanadine
4.	Phosphotransferases (Kinase)
5.	Tyrosine Kinase Inhibitors
6.	bafetinib